|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||82.59 - 83.47|
|52 Week Range||73.69 - 89.09|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||2.25 (2.77%)|
|1y Target Est||N/A|
INDIANAPOLIS, May 23, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that Sue Mahony, Ph.D., senior vice president of Lilly and president of Lilly Oncology, will retire at the end of August after 18 years of service with the company. Mahony is also a member of Lilly's executive committee. "On behalf of our executive team and the company, I want to thank Sue for her leadership over the past 18 years," said David A. Ricks, Lilly's chairman and chief executive officer.
GREENFIELD, Ind., May 23, 2018 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (LLY), and Heifer International mark a 10-year milestone in their journey that shares the upcoming World Hunger Day mission – empowering people to create a food secure world. Since 2008, Elanco and its employees have joined forces to give nearly $5 million to Heifer International's efforts to achieve food security across the globe. Through eight projects, Elanco and Heifer International have created more access to meat, milk and eggs through placing 35,600 animals, including cows, swine, poultry, goats, sheep and chickens in Zambia, Cambodia, India, China, Ecuador and Bangladesh.
"Up to 63 percent of psoriasis patients will be impacted by psoriasis involving the genital area over the course of their disease," said Pete Salzmann, vice president, Lilly Immunology. "However, there remains a serious unmet need for patients seeking treatment options.
Major equities: AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Co. (NYSE: BMY), Eli Lilly and Co. (NYSE: LLY), and GW Pharmaceuticals PLC (NASDAQ: GWPH). All you have to do is sign up today for this free limited time offer by clicking the link below.
LONDON, UK / ACCESSWIRE / May 17, 2018 / If you want access to our free research report on Eli Lilly and Co. (NYSE: LLY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LLY as the Company's latest news hit the wire. On May 15, 2018, the Company announced that a Phase-3 study evaluating galcanezumab in patients with episodic cluster headache met its primary endpoint, demonstrating statistically significant differences in the reduction of weekly cluster headache attacks compared to placebo across weeks one to three of the two-month, double-blind treatment period. There were also a statistically significantly greater percentage of patients treated with galcanezumab who achieved at least a 50% reduction in weekly cluster headache attacks compared to placebo at Week 3, the gated secondary endpoint.
First presentation of findings from the ramucirumab REACH-2 study - the first positive Phase 3 hepatocellular carcinoma trial in a biomarker-selected population Research across the MONARCH clinical development ...
INDIANAPOLIS, May 15, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that galcanezumab met its primary endpoint in a Phase 3 study of patients with episodic cluster headache, demonstrating statistically significant differences in the reduction of weekly cluster headache attacks compared to placebo across weeks one to three of the two-month, double-blind treatment period. A statistically significantly greater percentage of patients treated with galcanezumab also achieved at least a 50 percent reduction in weekly cluster headache attacks compared to placebo at Week 3, the gated secondary endpoint. The observed safety and tolerability profile was consistent with previous studies that evaluated galcanezumab for the prevention of migraine.
WeissLaw is investigating whether ARMO's Board acted to maximize shareholder value prior to entering into the agreement. Notably, at least one analyst set a target price of $75.00 per share, or $25.00 above the offer price. Moreover, the deal is a strategic transaction that will expand LLY's drug portfolio and provide LLY a foothold in the very lucrative cancer immunotherapy industry.
INDIANAPOLIS, May 14, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced an agreement to acquire AurKa Pharma, Inc., a company established by TVM Capital Life Science to develop oncology compound AK-01, an Aurora kinase A inhibitor that was originally discovered at Lilly. The compound is a potential first-in-class asset that AurKa Pharma is studying in Phase 1 clinical trials in multiple types of solid tumors. AurKa Pharma's asset, AK-01, has been shown to be highly selective for Aurora A, with potential clinical benefit observed in Phase 1 studies.
INDIANAPOLIS , May 11, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 22, 2018 . Enrique Conterno , senior vice president of Lilly ...
INDIANAPOLIS and REDWOOD CITY, Calif., May 10, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and ARMO BioSciences, Inc. (ARMO) today announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction. ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates designed to activate the immune system of cancer patients to recognize and eradicate tumors.
Indiana-based company adds Michael-Bryant Hicks to leadership team GREENFIELD, Ind. , May 10, 2018 /PRNewswire/ -- Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), named Michael-Bryant ...
INDIANAPOLIS , May 7, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2018 of $0.5625 per share on outstanding common ...
INDIANAPOLIS, May 1, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and Indiana University's Richard M. Fairbanks School of Public Health at IUPUI announced today the launch of a new neighborhood-based, data-driven pilot in Indianapolis to help address the high incidence of diabetes. Building on similar efforts Lilly has developed in lower-income communities in Mexico, India and South Africa, the $7 million, five-year program will focus on three Indianapolis neighborhoods with significant health disparities and high rates of diabetes: the Coalition of Northeast Neighborhoods, Northwest Neighborhood and Near Westside Neighborhood.
Dr. Gandhi is currently the Director of Thoracic Medical Oncology and an associate professor of medicine at the New York University (NYU) School of Medicine. After joining Lilly, she will lead a team of scientists that oversees the Lilly Oncology immunotherapy portfolio.
INDIANAPOLIS , April 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018 . Christi Shaw ...
- Collaboration between China's National Center for Cardiovascular Diseases and Lilly aims to improve care for people living with Type 2 diabetes in China - The Lilly and NCCD collaboration will address ...
- First-quarter 2018 revenue increased 9 percent, driven primarily by the increased demand for new pharmaceutical products, while operating expenses declined 5 percent. - First-quarter 2018 earnings per ...
INDIANAPOLIS, April 24, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today results from a post-hoc subgroup analysis which demonstrated efficacy of galcanezumab in patients with episodic and chronic migraine who previously failed to respond to two or more preventive therapies. Detailed results from a new subgroup analysis of three Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) evaluating galcanezumab will be presented today as part of the "Best of Headache" platform session at the American Academy of Neurology (AAN) annual meeting in Los Angeles. The U.S. Food and Drug Administration (FDA) is reviewing galcanezumab for the prevention of migraine in adults.
INDIANAPOLIS, April 23, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced today that the U.S. Food and Drug Administration's (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate. While the Advisory Committee unanimously supported the efficacy of the 4-mg dose of baricitinib, it did not recommend approval of the 4-mg dose of baricitinib for the proposed indication based on the adequacy of the safety and benefit-risk profiles.
Christopher Jensen to join Indiana-based Animal Health Company's Leadership Team GREENFIELD, Ind. , April 23, 2018 /PRNewswire/ -- Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: ...
Significant improvement in primary endpoint of progression-free survival previously reported; Improvement in objective response rate observed; Positive trend in overall survival did not reach statistical ...
INDIANAPOLIS, April 20, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational treatments for migraine, at the American Academy of Neurology (AAN) annual meeting taking place April 21-27 in Los Angeles. Lilly will highlight a new analysis from three Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) evaluating galcanezumab in patients who previously failed two or more preventive therapies as part of the "Best in Headache" platform session on Tuesday, April 24. Galcanezumab is a once-monthly, self-administered calcitonin gene-related peptide (CGRP) antibody currently under review by the U.S. Food and Drug Administration (FDA) for the prevention of migraine in adults.
RIDGEFIELD, Conn. and INDIANAPOLIS, April 16, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY) today announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance® on the progression of kidney disease and the occurrence of cardiovascular death, in adults with established chronic kidney disease with and without diabetes. EMPA-KIDNEY will be independently conducted, analyzed and reported by the Medical Research Council Population Health Research Unit at the University of Oxford (MRC PHRU), which is based in the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), in partnership with the Duke Clinical Research Institute.
Stock Monitor: China Pharma Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free research report on Eli Lilly and Co. (NYSE: LLY ) ("Eli ...